Friday, March 19, 08:01 am IST
Hot Searches:  inflationcementBharti
| Feedback
Moneycontrol » News Center » Business » Business News

Want more about Business to land in your mailbox?

Set an alert here

Gilead Sciences counts on Indian pharma companies

Published on Mon, May 14, 2007 at 08:52   |  Updated at Mon, May 14, 2007 at 14:07  |  Source : Moneycontrol.com
Google Buzz

New Delhi May 13

Despite a pre-grant challenge to its Indian patent application due to be heardsoon, the California-based Gilead Sciences is hopeful of making its licence agreements with 10 Indian companies for its HIV drugs, the model for marketing other drugs in the future.

"Making drugs for life threatening diseases available to resource constrained sub-Saharan African countries has been a particular challenge for western companies. We believe that Indian pharma companies with their cost advantage, manufacturing capacities and distribution can help our drugs reach these markets," Mr Gregg Alton, Senior Vice-President and General Counsel, Gilead Sciences told Business Line.


RSS feed for news
Click here

New Model

The agreements entered into since last September cover two drugs, Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate), and allows the Indian partners, which include Aurobindo Pharma, Hetero Drugs, Matrix and Ranbaxy to make any combination of the drugs and more importantly, fix the market price.

Gilead, which gets a five per cent royalty, is hopeful of seeing the Indian drugs reach markets in the next three to six months. If the model is successful, it hopes to replicate it around the world and for other drugs in the future.

Gilead is keen to point out that the agreement with Indian pharma companies also covers technology transfer of the API and the finished antiretrovirals. "The rationale behind multiple partners is to see a high-volume, low-margin business for these drugs," said Mr Alton.

contd on page 2...

CEO Wall See All

MS Banga

MS Banga

President - Global Foods, Home, and Personal Care Business

Unilever

Right time to move on, Unilever healthy again: Vindi Banga

VVS Murthy

VVS Murthy

CFO

Dishman Pharma

Dishman Pharma invests $20m in new API facility

T Srinivasa Rao

T Srinivasa Rao

VP-Finance

Rain Commodities

See better op margins, volumes in CY10: Rain Commodities

Rahul Shah

Rahul Shah

Executive Director

Nitin Fire Protection

See 20-25% revenue growth in FY11: Nitin Fire Protection

WHAT OTHERS LIKE
  • Most Read
  • Most Viewed
24 Hours
7 Days
1 Month
NEWS FROM OUR PARTNERS
©Network 18, 2010. All Rights Reserved